ONYDA XR Drug Patent Profile
✉ Email this page to a colleague
When do Onyda Xr patents expire, and when can generic versions of Onyda Xr launch?
Onyda Xr is a drug marketed by Tris Pharma Inc and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries.
The generic ingredient in ONYDA XR is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Onyda Xr
A generic version of ONYDA XR was approved as clonidine hydrochloride by ACTAVIS ELIZABETH on December 16th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ONYDA XR?
- What are the global sales for ONYDA XR?
- What is Average Wholesale Price for ONYDA XR?
Summary for ONYDA XR
| International Patents: | 21 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ONYDA XR |
| What excipients (inactive ingredients) are in ONYDA XR? | ONYDA XR excipients list |
| DailyMed Link: | ONYDA XR at DailyMed |
Pharmacology for ONYDA XR
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
US Patents and Regulatory Information for ONYDA XR
ONYDA XR is protected by two US patents.
Patents protecting ONYDA XR
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR DELIVERING AN EFFECTIVE AMOUNT OF CLONIDINE FOR A 24-HOUR PERIOD USING A SINGLE ORAL CLONIDINE COMPOSITION ACCORDING TO CLAIM 1 PRIOR TO BED TIME
Modified release formulations containing drug-ion exchange resin complexes
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | ONYDA XR | clonidine hydrochloride | SUSPENSION, EXTENDED RELEASE;ORAL | 217645-001 | May 24, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Tris Pharma Inc | ONYDA XR | clonidine hydrochloride | SUSPENSION, EXTENDED RELEASE;ORAL | 217645-001 | May 24, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ONYDA XR
See the table below for patents covering ONYDA XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 101495146 | ⤷ Sign Up | |
| Denmark | 2018160 | ⤷ Sign Up | |
| Denmark | 2428205 | ⤷ Sign Up | |
| Canada | 2645855 | FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES) | ⤷ Sign Up |
| European Patent Office | 2428205 | Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
